A Phase 2 interventional study of AZD9833 and Fulvestrant in Advanced ER-Positive HER2-Negative Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 85 sites in 16 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Neoplasm Metastasis by AstraZeneca — 6 open to participants now, 23 under way, 14 of them phase 3. Neoplasm Metastasis · AstraZeneca.
Among the 60 studies in Neoplasm Metastasis by AstraZeneca, this one is the 19th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 in phase 2, reaches primary completion later than 3 of the 22 other live ones, and was the 42nd registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →6 of the 60 studies in Neoplasm Metastasis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, France, Germany and 6 more countries
Ages 18–130
AstraZeneca · Sites in United States, China, France and 3 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+ · Women only
AstraZeneca · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
By country, each count listing its studies:
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 19 · Phase 3 19
First in 1998; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 102 across the 55 interventional studies, 310 across the 3 observational. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
5 of the studies in Neoplasm Metastasis by AstraZeneca that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06103864Phase 3AstraZenecaA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | 2027-07-28 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT06713369AstraZenecaAZD5305 hADME in Patients With Advanced Solid Malignancies | 2026-12-31 |
| NCT06792695AstraZenecaA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 60 studies in Neoplasm Metastasis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.
Post-menopausal women with histologically or cytologically confirmed metastatic or loco-regionally recurrent ER-positive HER2-negative breast cancer before randomization and fulfilling all of the inclusion criteria and none of the exclusion criteria will be included.
After the screening visit and confirmation of eligibility, patients will be randomly assigned in a 1:1:1:1 ratio to receive 1 of the following 4 treatments, consisting of 4-week treatment cycles until disease progression (assessed by the Investigator as defined by Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1):
As of December 2020, the Sponsor stopped enrolment to Dose C.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior endocrine therapy as follows:
Washout from prior tamoxifen: 4 months to elapse from last tamoxifen dose to pre-dose on-study biopsy.
Exclusion Criteria:
Intervention with any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patients will receive AZD9833 (Dose A).
Drug: AZD9833
The patients will receive AZD9833 (Dose B).
Drug: AZD9833
The patients will receive AZD9833 (Dose C).
Drug: AZD9833
The patients will receive Fulvestrant (500 mg).
Drug: Fulvestrant
Dosage formulation: AZD9833 tablets will be administered orally.
Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
Progression-free Survival (PFS)
PFS was assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1. PFS was defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or received another anti-cancer therapy prior to progression. Disease progression was defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
Time frame: From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months)
Objective Response Rate (ORR)
ORR was assessed by the Investigator as defined by RECIST version 1.1. The ORR was defined as investigator assessed Complete Response or Partial Response prior to progression in patients with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Adjusted response rate was presented in this analysis. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
Time frame: From screening until disease progression (up to data cut-off of 29 months)
Duration of Response (DoR)
DoR was assessed by the Investigator as defined by RECIST version 1.1. The DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.
Time frame: From screening until disease progression or last evaluable assessment in the absence of progression (up to data cut-off of 29 months)
Percentage Change in Tumour Size at 16 Weeks
The percentage change in tumour size at 16 weeks was obtained for each patient, based on RECIST measurements taken at baseline and at 16 weeks. Tumour size is the sum of the longest diameters of the target lesions (TLs). Percentage change in the sum of longest TLs diameters at 16 weeks was measured.
Time frame: At Week 16
Overall Survival (OS)
The OS was defined as the time from randomisation to death due to any cause.
Time frame: From the date of randomisation until death (up to data cut-off of 29 months)
Clinical Benefit Rate at 24 Weeks (CBR24)
Clinical benefit rate was defined as patients with best objective response of complete response or partial response in the first 25 weeks or who have stable disease for at least 23 weeks after randomization. Adjusted response rate was presented in this analysis. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
Time frame: At Week 24
Plasma Concentrations of AZD9833
The plasma concentrations of AZD9833 at steady state were evaluated.
Time frame: Cycle 1 Day 15 (pre-dose), Cycle 1 Day 15 (2h), Cycle 1 Day 15 (4h) and Cycle 2 Day 1 (pre-dose), (each cycle is 28 days in length)
Percent Change From Baseline in ER and PgR Expression and Ki67 Labelling Index
The pharmacodynamics of AZD9833 and fulvestrant in a subgroup of patients.
Time frame: From baseline to Cycle 2 Day 1 (each cycle is 28 days in length)
Changes From Baseline in Health Related Quality of Life (HRQoL)
To evaluate the effect of AZD9833 and fulvestrant on the patients' health-related quality of life, as assessed by patient completed HRQoL questionnaires.
Time frame: From Day 1 until end of treatment and safety follow up (up to data cut-off of 29 months)
Number of Patients With Adverse Events
The safety and tolerability of AZD9833 when compared to fulvestrant in women with advanced ER-positive HER2-negative breast cancer was evaluated.
Time frame: From the date of first dose up to the safety follow-up period (28 days after last dose of AZD9833 and 56 days after last dose of fulvestrant) (up to data cut-off of 29 months)
The patients were enrolled at 82 sites in 16 countries from 22 April 2020 to 30 August 2022. The study is ongoing.
| Milestone | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg |
|---|---|---|---|---|
| Started | 74 | 73 | 20 | 73 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 74 | 73 | 20 | 73 |
| Withdrew: Ongoing in the study | 41 | 51 | 12 | 39 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Death | 22 | 13 | 7 | 19 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 0 |
| Withdrew: Other | 1 | 2 | 0 | 6 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 4 | 0 | 9 |
PFS was assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1. PFS was defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or received another anti-cancer therapy prior to progression. Disease progression was defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
| Months | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg |
|---|---|---|---|---|
| Progression-free Survival (PFS) | 7.2 (3.7 to 10.9) | 7.7 (5.5 to 12.9) | 6.3 (1.9 to NA) | 3.7 (2.0 to 6.0) |
ORR was assessed by the Investigator as defined by RECIST version 1.1. The ORR was defined as investigator assessed Complete Response or Partial Response prior to progression in patients with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Adjusted response rate was presented in this analysis. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
| Percentage (%) | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg |
|---|---|---|---|---|
| Objective Response Rate (ORR) | 15.7 | 17.1 | 25.2 | 11.6 |
DoR was assessed by the Investigator as defined by RECIST version 1.1. The DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.
Results for this outcome have not been posted.
The percentage change in tumour size at 16 weeks was obtained for each patient, based on RECIST measurements taken at baseline and at 16 weeks. Tumour size is the sum of the longest diameters of the target lesions (TLs). Percentage change in the sum of longest TLs diameters at 16 weeks was measured.
Results for this outcome have not been posted.
The OS was defined as the time from randomisation to death due to any cause.
Results for this outcome have not been posted.
Clinical benefit rate was defined as patients with best objective response of complete response or partial response in the first 25 weeks or who have stable disease for at least 23 weeks after randomization. Adjusted response rate was presented in this analysis. Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
| Percentage (%) | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg |
|---|---|---|---|---|
| Clinical Benefit Rate at 24 Weeks (CBR24) | 48.8 | 51.0 | 42.4 | 39.1 |
The plasma concentrations of AZD9833 at steady state were evaluated.
| ng/ml | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg |
|---|---|---|---|
| Cycle 1 Day 15 (pre-dose) | 22.8387 ± 84.3207 | 41.0856 ± 148.5806 | 108.1351 ± 157.3080 |
| Cycle 1 Day 15 (2h) | 51.9098 ± 94.4632 | 96.2038 ± 164.5328 | 302.1254 ± 66.9155 |
| Cycle 1 Day 15 (4h) | 54.5098 ± 87.2152 | 95.5360 ± 160.0032 | 289.1464 ± 68.1607 |
| Cycle 2 Day 1 (pre-dose) | 24.2895 ± 88.4140 | 34.2592 ± 245.9897 | 115.8558 ± 156.4858 |
The pharmacodynamics of AZD9833 and fulvestrant in a subgroup of patients.
Results for this outcome have not been posted.
To evaluate the effect of AZD9833 and fulvestrant on the patients' health-related quality of life, as assessed by patient completed HRQoL questionnaires.
Results for this outcome have not been posted.
The safety and tolerability of AZD9833 when compared to fulvestrant in women with advanced ER-positive HER2-negative breast cancer was evaluated.
| Participants | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg |
|---|---|---|---|---|
| Any Adverse Event (AE) | 57 | 66 | 19 | 50 |
| Any AE causally related to treatment | 39 | 49 | 14 | 13 |
| Any AE of CTCAE grade 3 or higher | 9 | 17 | 3 | 11 |
| Any AE of CTCAE grade 3 or higher, causally related to treatment | 1 | 2 | 1 | 0 |
| Any AE with outcome = death | 0 | 1 | 0 | 0 |
| Any AE with outcome = death, causally related to treatment | 0 | 0 | 0 | 0 |
| Any Serious Adverse Event (SAE) | 6 | 7 | 2 | 4 |
| Any SAE, causally related to treatment | 3 | 2 | 1 | 0 |
| Any SAE causing discontinuation of treatment | 1 | 0 | 0 | 0 |
| Any SAE causing discontinuation of treatment, causally related to treatment | 1 | 0 | 0 | 0 |
| Any AE leading to discontinuation of treatment | 2 | 0 | 2 | 0 |
| Any AE leading to discontinuation of treatment, causally related to treatment | 2 | 0 | 0 | 0 |
| Any AE leading to dose reduction | 1 | 9 | 4 | 0 |
| Any AE leading to dose interruption | 11 | 16 | 4 | 3 |
Collected over From the date of first dose up to the safety follow-up period (28 days after last dose of AZD9833 and 56 days after last dose of fulvestrant) (up to data cut-off of 29 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD9833 75mg | 23/74 (31.1%) | 6/74 (8.1%) | 44/74 (59.5%) |
| AZD9833 150mg | 14/73 (19.2%) | 7/73 (9.6%) | 61/73 (83.6%) |
| AZD9833 300mg | 7/20 (35%) | 2/20 (10%) | 17/20 (85%) |
| Fulvestrant 500 mg | 21/73 (28.8%) | 4/73 (5.5%) | 31/73 (42.5%) |
| Event | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg |
|---|---|---|---|---|
| Breast cellulitisInfections and infestations | 0/74 | 1/7 | 0/20 | 0/73 |
| COVID-19 pneumoniaInfections and infestations | 0/74 | 1/7 | 0/20 | 0/73 |
| COVID-19Infections and infestations | 0/74 | 0/7 | 1/20 | 0/73 |
| International normalised ratio increasedInvestigations | 0/74 | 0/73 | 1/20 | 0/73 |
| HyponatraemiaMetabolism and nutrition disorders | 0/74 | 1/73 | 0/20 | 0/73 |
| Cerebrovascular accidentNervous system disorders | 0/74 | 1/73 | 0/20 | 0/73 |
| Atrial fibrillationCardiac disorders | 0/74 | 1/73 | 0/20 | 1/73 |
| Atrial tachycardiaCardiac disorders | 0/74 | 1/73 | 0/20 | 0/73 |
| Supraventricular tachycardiaCardiac disorders | 0/74 | 0/73 | 0/20 | 1/73 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/74 | 1/73 | 0/20 | 1/73 |
| Event | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg |
|---|---|---|---|---|
| PhotopsiaEye disorders | 9/74 | 18/73 | 7/20 | 0/73 |
| BradycardiaCardiac disorders | 0/74 | 12/73 | 6/20 | 0/73 |
| FatigueGeneral disorders | 4/74 | 14/73 | 4/20 | 3/73 |
| AnaemiaBlood and lymphatic system disorders | 7/74 | 11/73 | 1/20 | 5/73 |
| AstheniaGeneral disorders | 6/74 | 11/73 | 2/20 | 5/73 |
| DiarrhoeaGastrointestinal disorders | 4/74 | 4/73 | 3/20 | 2/73 |
| Alanine aminotransferase increasedInvestigations | 1/74 | 6/73 | 3/20 | 4/73 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/74 | 9/73 | 2/20 | 3/73 |
| COVID-19Infections and infestations | 4/74 | 4/73 | 2/20 | 3/73 |
| HyponatraemiaMetabolism and nutrition disorders | 0/74 | 2/73 | 2/20 | 1/73 |
Full Analysis Set (FAS) consisted of all randomised patients, with treatment groups assigned in accordance with the randomisation, regardless of the actual treatment received.
| Age, Continuous(Years) | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg | Total |
|---|---|---|---|---|---|
| Mean | 61.2 ± 9.56 | 61.7 ± 9.68 | 59.9 ± 10.72 | 59.3 ± 11.08 | 60.7 ± 10.16 |
| Sex: Female, Male(Participants) | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg | Total |
|---|---|---|---|---|---|
| Female | 74 | 73 | 20 | 73 | 240 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | AZD9833 75mg | AZD9833 150mg | AZD9833 300mg | Fulvestrant 500 mg | Total |
|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 0 | 2 | 2 |
| White | 71 | 70 | 20 | 65 | 226 |
| Other | 3 | 3 | 0 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2020 to primary completion in Aug 2022, 28 months.
Results were first posted in Dec 2023, 1 year 3 months after primary completion.
Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 28 months is below that.
Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD9833